Evidence map›Paper›PMID 41888503›Full record

Trial reportCNS drugs2026

Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru

Igor Bendik, Mareike Beck, Anu Manderna, Franz F Roos, Jun Wang, Deanna McCarthy, Christiane Schweiggert, Ahmed Besheer, Josh Baisley, Zdravka Misic and 4 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase IComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in CNS drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06578455 (A Randomized, Open-Label, 4-Way Crossover, Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06578455 phase1completednot on this map

A Randomized, Open-Label, 4-Way Crossover, Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions

TypeinterventionalSponsordsm-firmenich Switzerland AGRan2024 to 2024Enrolled32ConditionsCBD Pharmacokinetics, Healthy ParticipantsArmsCannabidiol (CBD) Powder, Cannabidiol 100 MG/ML [Epidiolex]
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Igor Bendik *Health Nutrition & Care, dsm-firmenich, Wurmisweg 576, Campus Building 245, 4303, Kaiseraugst, Switzerland. igor.bendik@dsm-firmenich.com.
Mareike Beck *Science & Research, dsm-firmenich, Kaiseraugst, Switzerland.
Anu MandernaNutrasource Pharmaceutical & Nutraceutical Services Inc., Guelph, ON, Canada.
Franz F RoosScience & Research, dsm-firmenich, Kaiseraugst, Switzerland.
Jun WangNutrasource Pharmaceutical & Nutraceutical Services Inc., Guelph, ON, Canada.
Deanna McCarthyHealth Nutrition & Care, dsm-firmenich, Wurmisweg 576, Campus Building 245, 4303, Kaiseraugst, Switzerland.
Christiane SchweiggertScience & Research, dsm-firmenich, Kaiseraugst, Switzerland.
Ahmed BesheerScience & Research, dsm-firmenich, Kaiseraugst, Switzerland.
Josh BaisleyNutrasource Pharmaceutical & Nutraceutical Services Inc., Guelph, ON, Canada.
Zdravka MisicHealth Nutrition & Care, dsm-firmenich, Wurmisweg 576, Campus Building 245, 4303, Kaiseraugst, Switzerland.
Bernd MusslerHealth Nutrition & Care, dsm-firmenich, Wurmisweg 576, Campus Building 245, 4303, Kaiseraugst, Switzerland.
Adam KuttenkeulerNutrasource Pharmaceutical & Nutraceutical Services Inc., Guelph, ON, Canada.
Daniele PiomelliRhizotomos Consulting, Irvine, CA, USA.
Szabolcs PéterHealth Nutrition & Care, dsm-firmenich, Wurmisweg 576, Campus Building 245, 4303, Kaiseraugst, Switzerland. szabolcs.peter@dsm-firmenich.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmerging evidence indicates that cannabidiol (CBD) may offer meaningful therapeutic benefits across neurological, pain, and psychiatric disorders. Cannabidiol is already approved for the treatment of pediatric epilepsy. Owing to its high lipophilicity, it is typically delivered in oil-based formulations to overcome the low oral bioavailability of pure CBD. However, pharmacokinetic (PK) and safety data remain limited across different CBD formulations. This study evaluated the PK profile, tolerability, and safety of an encapsulated powdered emulsion formulation (CBtru

methodsThis Phase I, single-center, open-label, randomized, 4-way crossover PK trial was conducted in healthy adults. All participants received a single 400-mg dose of CBtru

resultsUnder fasted conditions, CBtru

conclusionBoth formulations demonstrated distinct PK profiles under fasted and fed conditions. CBtru CLINICALTRIALS: gov ID number: NCT06578455.

Indexed as

CannabidiolAdministration, OralAdolescentAdultArea Under CurveBiological AvailabilityCross-Over StudiesEmulsionsFastingFemaleHealthy VolunteersHumansMaleMiddle AgedPowdersYoung AdultCannabidiolEmulsionsPowders

Identifiers

PMID41888503
PMCPMC13095987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.